Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19



Rating:

Share or cite this content

Citations should be made in the following way:
C. Pinto (Salvador (BA), Brazil), A. Vale (Salvador (BA), Brazil), P. Lauton (Salvador (BA), Brazil), L. Costa (Salvador (BA), Brazil), A. Lemos (Salvador (BA), Brazil). Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study. 3557

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Withdrawal of high-dose inhaled corticosteroids in COPD patients with mild or moderate airflow limitation: a feasibility study in primary care. Source: International Congress 2019 – Multimorbidity in airway diseases and appropriate inhaled corticosteroid use in COPD Year: 2019 Effect of ICS withdrawal on COPD exacerbations in patients on triple therapy at baseline Source: International Congress 2018 – COPD management Year: 2018 Clinical and economic impact of inhaled corticosteroid withdrawal in Spanish COPD patients treated with triple therapy Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Utility of high dose inhaled fluticasone therapy for the early management of acute exacerbations of asthma Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Comparison of the efficacy of cicleosonide with budesonide in mild to moderate asthma patients after step-down therapy Source: Annual Congress 2011 - Asthma management and response Year: 2011 The effect of combined β2-agonist and anticholinergic inhaled therapy in patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 Are COPD patients taking triple combination inhalers being overmedicated during acute exacerbations? Source: International Congress 2019 – COPD treatment: cohorts and real-world studies Year: 2019 Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Efficacy of a combination therapy with single inhaler budesonide/formoterol in the treatment of acute exacerbations of COPD (AECOPD) Source: Eur Respir J 2004; 24: Suppl. 48, 252s Year: 2004 Long-term azithromycin therapy in severe COPD with repeated exacerbations Source: Annual Congress 2010 - COPD exacerbation Year: 2010 Treatment with inhaled corticosteroids (ICS) in patients with COPD: possible way of optimisation Source: Annual Congress 2009 - Drug effects in COPD Year: 2009 Efficacy of different dosing regimens of azithromycin in a real-world severe asthma cohort Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results Source: Eur Respir J 2009; 34: 641 Year: 2009 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy Source: International Congress 2015 – Advances in the future treatment of COPD Year: 2015 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014